Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2010

View Archived Issues

Novartis gains exclusive rights to Debiopharm's alisporivir for hepatitis C

ALK-Abello reports final follow-up results from GT-08 trial of Grazax

VaxGen stockholder vote insufficient to approve merger with OXiGENE

Westaim merges with Nucryst to form Westaim Holdings

SciClone and Sigma-Tau report topline results of Zadaxin trial in H1N1

Ono Pharmaceutical reports results from third quarter of 2009, ended December 31

Phase I data support safety and tolerability of ADMVA HIV candidate vaccine

Denosumab superior to Zometa in prostate cancer patients with bone metastases

Hsp32 implicated in protective effects of celastrol in hair cell death

Palatin Technologies doses first male cohort in bremelanotide safety trial

Baclofen shown to inhibit salicylate and noise-induced tinnitus in rats

Minocycline ameliorates neomycin-induced hearing loss in gerbils

Novel PET imaging agents identified by Merck & Co.

Takeda studies concomitant use of dexlansoprazole and other PPIs with Plavix

Sirtris Pharmaceuticals discovers SIRT activators

Novel ACC inhibitors in early development at Pfizer

Progenics reports the identification of a wide range of PI3K inhibitors

GSK claims novel triple monoamine reuptake inhibitors for affective disorders

Kamada enrolls first patient in pivotal study of inhaled AAT

Xoma initiates phase IIb dose-finding XOMA-052 trial in type 2 diabetes

Psyadon initiates clinical trial of ecopipam in Lesch-Nyhan disease

Chelsea Therapeutics advances neurogenic orthostatic hypotension program

Tibotec's Prezista approved in Canada as part of combination therapy for pediatric HIV

AnaptysBio and Merck & Co. enter into antibody development collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...